We Accept amex

Formerly known as Maylips.com

info@directdoctorsupply.com+1-800-325-7104

Logo Logo
Track delivery Wishlist
  • 0 $ 0.00
  • Products
    • All Products
    • Peptides NEW
    • Anaesthetics
    • Body Sculpting
    • Botulinum Toxin
    • Cannulas and Needles
    • Cellular Rejuvenation
    • Dermal Filler Removal
    • Dermal Fillers
      • Biostimulators
      • HA Dermal Fillers
      • Korean Dermal Fillers
      • Polynucleotides
      • Skinboosters
    • Exosomes
    • Eyelash Enhancers
    • Fat Removal
    • Gynecology
    • Mesotherapy
    • IV Therapy
    • Orthopedic Injections
    • Peels and Masks
    • PRP Kits
    • Skincare
    • Threads
      • PCLA Threads
      • PDO Threads
      • PLA Threads
    • Weight Loss
  • Brands
    • ALIAXIN®
    • ALIDYA™
    • AQUALYX®
    • AZZALURE®
    • BCN
    • BELLAST®
    • BELOTERO®
    • BIOREPEELCL3®
    • BOCOUTURE® (XEOMIN®)
    • BOTOX®
    • CAREGEN
    • CINGAL®
    • CRESPINE®
    • CROMA
    • CYTOCARE
    • DEPO-PROVERA®
    • DERMALAX™
    • DESIRIAL®
    • DUROLANE®
    • DYSPORT®
    • EJAL
    • ELLANSÉ™
    • EMLA™
    • Euflexxa
    • FILLMED®
    • FILORGA®
    • GARDASIL®
    • HArmonyCA™
    • HYACORP
    • HYAFILIA®
    • HYALGAN®
    • HYMOVIS®
    • HYNIDASE®
    • INTRALINE®
    • JALUPRO®
    • JAYDESS®
    • JUVÉDERM®
    • KARISMA
    • LEMONBOTTLE
    • LANLUMA
    • LIPORASE®
    • MEDIDERMA®
    • MESO-RELLE®
    • MESOESTETIC®
    • MICRONJET™
    • MIRENA®
    • MONOVISC®
    • MOUNJARO®
    • NEAUVIA™
    • NEURAMIS®
    • NEXPLANON®
    • NITHYA
    • NOVERA COMPOUNDS
    • NUCLEOFILL™
    • ORTHOVISC®
    • OZEMPIC®
    • PERFECTHA®
    • PLASMOLIFTING™
    • PROFHILO®
    • ​PROSTROLANE®
    • PRX-T33®
    • RADIESSE®
    • RAINBOW
    • REFINE
    • REJURAN®
    • REJUVANAD+
    • REFINE
    • RESTYLANE®
    • REVANESSE®
    • REVOFIL
    • REVOLAX™
    • SAXENDA®
    • SAYPHA®
    • SCULPTRA®
    • SESDERMA®
    • SILHOUETTE
    • SMB®
    • SOFTFIL®
    • STYLAGE®
    • SUNEKOS®
    • SUPARTZ®
    • SYNVISC®
    • T-SAFE®
    • TEOSYAL®
    • ​THERASET®
    • VISCODERM®
    • WEGOVY®
    • XEOMIN®
    • ZO®
  • Peptides NEW
  • Sale
  • Shipping
  • Contact
  • About Us
  • Referral Program
  • Blog
  • Sign In / Register
Logo Logo
Menu
Close
Wishlist
  • Products
    • All Products
    • Peptides NEW
    • Anaesthetics
    • Body Sculpting
    • Botulinum Toxin
    • Cannulas and Needles
    • Cellular Rejuvenation
    • Dermal Filler Removal
    • Dermal Fillers
      • Biostimulators
      • HA Dermal Fillers
      • Korean Dermal Fillers
      • Polynucleotides
      • Skinboosters
    • Exosomes
    • Eyelash Enhancers
    • Fat Removal
    • Gynecology
    • Mesotherapy
    • IV Therapy
    • Orthopedic Injections
    • Peels and Masks
    • PRP Kits
    • Skincare
    • Threads
      • PCLA Threads
      • PDO Threads
      • PLA Threads
    • Weight Loss
  • Brands
    • ALIAXIN®
    • ALIDYA™
    • AQUALYX®
    • AZZALURE®
    • BCN
    • BELLAST®
    • BELOTERO®
    • BIOREPEELCL3®
    • BOCOUTURE® (XEOMIN®)
    • BOTOX®
    • BOTULAX®
    • CAREGEN
    • CINGAL®
    • CRESPINE®
    • CROMA
    • CYTOCARE
    • DEPO-PROVERA®
    • DERMALAX™
    • DESIRIAL®
    • DUROLANE®
    • DYSPORT®
    • EJAL
    • ELLANSÉ™
    • EMLA™
    • Euflexxa
    • FILLMED®
    • FILORGA®
    • GARDASIL®
    • HArmonyCA™
    • HYACORP
    • HYAFILIA®
    • HYALGAN®
    • HYMOVIS®
    • HYNIDASE®
    • INNOTOX®
    • INTRALINE®
    • JALUPRO®
    • JAYDESS®
    • JUVÉDERM®
    • KAIMAX
    • KARISMA
    • LEMONBOTTLE
    • LETYBO®
    • LANLUMA
    • LIPORASE®
    • LIZTOX®
    • MEDIDERMA®
    • MEDITOXIN®
    • MESO-RELLE®
    • MESOESTETIC®
    • MICRONJET™
    • MIRENA®
    • MONOVISC®
    • MOUNJARO®
    • NABOTA® (JEUVEAU®)
    • NEAUVIA™
    • NEURAMIS®
    • NEXPLANON®
    • NITHYA
    • NOVERA COMPOUNDS
    • NUCLEOFILL™
    • ORTHOVISC®
    • OZEMPIC®
    • PERFECTHA®
    • PLASMOLIFTING™
    • PROFHILO®
    • ​PROSTROLANE®
    • PRX-T33®
    • RADIESSE®
    • RAINBOW
    • Re N Tox™
    • REFINE
    • REJURAN®
    • REJUVANAD+
    • REFINE
    • RESTYLANE®
    • REVANESSE®
    • REVOFIL
    • REVOLAX™
    • SAXENDA®
    • SAYPHA®
    • SCULPTRA®
    • SESDERMA®
    • SILHOUETTE
    • SMB®
    • SOFTFIL®
    • STYLAGE®
    • SUNEKOS®
    • SUPARTZ®
    • SYNVISC®
    • T-SAFE®
    • TEOSYAL®
    • ​THERASET®
    • VISCODERM®
    • WEGOVY®
    • XEOMIN®
    • ZO®
  • Peptides NEW
  • Sale
  • Shipping
  • Contact
  • About Us
  • Referral Program
  • Blog
  • Sign In / Register
  • 0 $ 0.00
Direct Doctor SupplyPeptides for ResearchWeight Loss & Metabolic PeptidesRetatrutide
Product Category
  • Anaesthetics (2)
  • Body Sculpting (4)
  • Botulinum Toxins (33)
  • Cannulas and Needles (13)
  • Cellular Rejuvenation (1)
  • Dermal Filler Removal (2)
  • Dermal Fillers (192)
  • Biostimulators (10)
  • HA Dermal Fillers (129)
  • Korean Dermal Fillers (28)
  • Polynucleotides (17)
  • Skinboosters (16)
  • Exosomes (1)
  • Eyelash Enhancers (1)
  • Fat Removal (3)
  • Gynecology (8)
  • IV Therapy (2)
  • Mesotherapy (23)
  • Orthopedic Injections (11)
  • Peels and Masks (23)
  • Peptides for Research (45)
  • Aesthetic & Cosmetic Peptides (1)
  • Brain, Cognitive & Nootropic Peptides (4)
  • Healing & Regenerative Peptides (6)
  • Immune & Thymic Peptides (4)
  • Longevity & Anti-Aging Peptides (7)
  • Muscle Growth & Performance Peptides (11)
  • Sexual Health & Hormonal Peptides (3)
  • Weight Loss & Metabolic Peptides (11)
  • PRP Kits (1)
  • Skincare (26)
  • Threads (28)
  • PCLA Threads (3)
  • PDO Threads (20)
  • PLA Threads (3)
  • Weight Loss (24)
Product Brand
  • ALIAXIN® (6)
  • ALIDYA™ (1)
  • AQUALYX® (1)
  • AZZALURE® (1)
  • BCN (12)
  • BELLAST® (3)
  • BELOTERO® (7)
  • BIOMEDICO (3)
  • BIOREPEELCL3® (2)
  • BOCOUTURE® (XEOMIN®) (3)
  • BOTOX® (6)
  • CAREGEN (2)
  • CINGAL® (1)
  • CRESPINE® (1)
  • CROMA (4)
  • CYTOCARE (4)
  • DEPO-PROVERA® (1)
  • DERMALAX™ (3)
  • DESIRIAL® (2)
  • DUROLANE® (1)
  • DYSPORT® (4)
  • EJAL (1)
  • ELLANSÉ™ (2)
  • EMLA™ (2)
  • EUFLEXXA® (1)
  • EXOJUV (1)
  • FILLMED® (14)
  • FILORGA® (2)
  • GARDASIL® (1)
  • HArmonyCA™ (1)
  • HYACORP (5)
  • HYAFILIA® (2)
  • HYALGAN® (1)
  • HYMOVIS® (1)
  • HYNIDASE® (1)
  • INTRALINE® (24)
  • JALUPRO® (5)
  • JAYDESS® (1)
  • JUVÉDERM® (13)
  • KARISMA (1)
  • LANLUMA (1)
  • LEMONBOTTLE (1)
  • LIPORASE® (1)
  • MEDIDERMA® (26)
  • MESO-RELLE® (2)
  • MESOESTETIC® (2)
  • MICRONJET™ (1)
  • MIRENA® (1)
  • MONOVISC® (1)
  • MOUNJARO® (9)
  • NEAUVIA™ (11)
  • NEURAMIS® (1)
  • NEXPLANON® (2)
  • NITHYA (3)
  • NOVERA COMPOUNDS (46)
  • NUCLEOFILL™ (8)
  • ORTHOVISC® (1)
  • OZEMPIC® (8)
  • PERFECTHA® (4)
  • PLASMOLIFTING™ (1)
  • PLINEST® (5)
  • PROFHILO® (3)
  • ​PROSTROLANE® (1)
  • PRX-T33® (1)
  • RADIESSE® (3)
  • RAINBOW (7)
  • REFINE (3)
  • REJURAN® (3)
  • REJUVANAD+ (2)
  • RENEFIL (3)
  • RESTYLANE® (10)
  • REVANESSE® (6)
  • REVOFIL (9)
  • REVOLAX™ (4)
  • SAXENDA® (1)
  • SAYPHA® (6)
  • SCULPTRA® (1)
  • SESDERMA® (10)
  • SILHOUETTE (3)
  • SMB® (1)
  • SOFTFIL® (6)
  • STYLAGE® (25)
  • SUNEKOS® (4)
  • SUPARTZ® (1)
  • SYNVISC® (2)
  • T-SAFE® (1)
  • TEOSYAL® (12)
  • ​THERASET® (1)
  • ULTRA V® (1)
  • VISCODERM® (2)
  • WEGOVY® (6)
  • XEOMEEN® (1)
  • XEOMIN® (4)
  • ZO® (3)

Retatrutide

Showing all 7 results

Sort By:
  • Retatrutide 10mg FrontRetatrutide 10mg Back
    Retatrutide 10mg
    $ 139.00
    Read More
    -+
  • Coming Soon
    Retatrutide 12mg FrontRetatrutide 12mg Back
    Retatrutide 12mg
    Read More
  • Retatrutide 15mg FrontRetatrutide 15mg Back
    Retatrutide 15mg
    $ 159.00
    Read More
    -+
  • Retatrutide 20mg FrontRetatrutide 20mg Back
    Retatrutide 20mg
    $ 169.00
    Read More
    -+
  • Retatrutide 30mg FrontRetatrutide 30mg Back
    Retatrutide 30mg
    $ 199.00
    Read More
    -+
  • Retatrutide 5mg FrontRetatrutide 5mg Back
    Retatrutide 5mg
    $ 99.00
    Read More
    -+
  • Retatrutide 60mg FrontRetatrutide 60mg Back
    Retatrutide 60mg
    $ 349.00
    Read More
    -+

Retatrutide is an investigational GLP-1, GIP, and glucagon receptor triple agonist developed by Eli Lilly, representing the broadest mechanistic profile among current weight loss and metabolic peptides in clinical development. Endocrinologists, obesity medicine specialists, and compounding pharmacists evaluating next-generation metabolic therapies will find a detailed review of the triple agonist mechanism, Phase 2 trial data, dosing considerations, and comparisons with approved alternatives in the guide below. Practitioners seeking sourcing direction for research-grade Retatrutide may contact the Direct Doctor Supply support team for guidance and documentation support.

Retatrutide Mechanism of Action: GLP-1, GIP & Glucagon Triple Agonism

Retatrutide is a GLP-1, GIP, and glucagon receptor triple agonist developed by Eli Lilly, currently under evaluation as a weight loss and metabolic peptide for obesity, insulin resistance, and type 2 diabetes. Unlike currently approved GLP-1 receptor agonists or dual agonists, Retatrutide simultaneously activates three distinct metabolic pathways. As of mid-2026, Retatrutide remains an investigational compound and is not FDA-approved. Primary Phase 3 readouts from the TRIUMPH program are currently ongoing. [3][4]

Retatrutide is a next-generation triple agonist designed to simultaneously activate GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it is currently being evaluated in the Phase 3 TRIUMPH clinical trial program. [3][4] Interest in the compound increased following Phase 2 findings published by Jastreboff et al. in The New England Journal of Medicine (2023), which reported substantial reductions in body weight. [1]

Some commentators have described Retatrutide as a potential “game changer in obesity pharmacotherapy,” though such characterizations should be interpreted within the context of currently available Phase 2 evidence rather than established clinical practice.

GLP-1 Receptor Agonism

The GLP-1 component of Retatrutide functions similarly to established agents such as Semaglutide. Targeting GLP-1 receptors contributes to appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion. Targeting GLP-1 has become the foundation of modern obesity pharmacotherapy and serves as the baseline mechanism across all three receptor classes activated by Retatrutide. [1]

GIP Receptor Agonism

Retatrutide’s GIP receptor activity adds a second metabolic pathway that may enhance insulin secretion and improve adipose tissue metabolism. This mechanism mirrors one component of Tirzepatide, which also incorporates GIP agonism alongside GLP-1. Early human data suggest that combining GLP-1 and GIP pathways may produce additive metabolic benefits compared with GLP-1 receptor agonism alone. [1][2]

Glucagon Receptor Agonism

The glucagon receptor component represents the primary mechanistic distinction of Retatrutide. Preclinical and early human data suggest glucagon receptor activation may increase energy expenditure, stimulate hepatic lipolysis, reduce liver fat accumulation, and elevate basal metabolic rate. [1]

Neither Semaglutide nor Tirzepatide incorporates this third mechanism, making glucagon receptor agonism the feature most frequently cited as differentiating Retatrutide from approved comparators.

Why Triple Agonism Matters

The rationale behind GLP-1, GIP, and glucagon triple agonism is that each receptor targets a distinct metabolic bottleneck. GLP-1 primarily influences appetite and satiety; GIP supports glucose regulation and adipose tissue metabolism; and glucagon may increase caloric expenditure and drive hepatic lipolysis. [1]

Together, these pathways may contribute to greater reductions in body weight than dual agonist approaches. All three pathways also converge on insulin sensitivity and glucose regulation, making Retatrutide relevant to research on type 2 diabetes and insulin resistance, as well as obesity. [1][2]

Retatrutide Before & After: Phase 2 Efficacy & Safety Data

Published efficacy data come primarily from the Phase 2 obesity trial reported by Jastreboff et al. in The New England Journal of Medicine (2023) and the Phase 2 type 2 diabetes trial by Rosenstock et al. in The Lancet (2023). These findings form the basis of most current discussions regarding Retatrutide’s clinical potential. [1][2]

Retatrutide Before and After Results

The most widely cited Retatrutide before-and-after findings come from the Phase 2 obesity study by Jastreboff et al., published in The New England Journal of Medicine in 2023. [1]

  • Participants receiving 8 mg weekly achieved a mean body weight reduction of approximately 23% (22.8%) at 48 weeks.
  • Participants receiving 12 mg weekly achieved a mean body weight reduction of approximately 24% (24.2%) at 48 weeks.

These outcomes substantially exceeded placebo and represent some of the largest weight reductions reported in a controlled obesity trial. All efficacy figures should be interpreted within the context of a Phase 2 study and do not constitute guaranteed clinical outcomes. [1]

Trials for Retatrutide

Current development activity is focused on the Phase 3 TRIUMPH program. [3][4] Phase 2 data provide the primary published evidence base at the time of writing. Phase 3 studies are designed to confirm efficacy and safety across larger, more diverse patient populations and will ultimately determine whether Phase 2 findings translate into broader clinical use.

Menopausal Weight Gain Considerations

Search interest frequently includes whether Retatrutide may help with menopausal weight gain. No randomized controlled trials have specifically evaluated Retatrutide in menopausal populations at the time of writing. Any discussion should therefore be considered extrapolated from general obesity trial data. Given the magnitude of weight-loss outcomes observed in Phase 2 studies, the mechanism is biologically plausible, but dedicated menopause-specific evidence is not yet available. [1]

Retatrutide Dosing: How Long Will 10mg Last & BAC Water Reconstitution

(Current as of mid-2026. All dosing information below is derived from clinical trial protocols. No FDA-validated prescribing protocol exists outside authorized clinical trial settings.)

Published Phase 2 studies evaluated doses ranging from 1 mg to 12 mg administered once weekly via subcutaneous injection, with gradual dose escalation over approximately 24 weeks before reaching target maintenance doses. [1][2]

Because Retatrutide remains investigational, no FDA-validated prescribing protocol currently exists outside authorized clinical trials.

At the once-weekly dosing schedule used in clinical trials, a 10 mg vial generally serves as a single high-dose treatment baseline. However, because clinical protocols use specific titration steps — such as 2 mg, 4 mg, 9 mg, or 12 mg — a 10 mg vial may yield multiple smaller starter doses, depending on the phase of the research protocol. Practitioners calculating research inventory requirements should account for titration schedules, maintenance dosing targets, and protocol-specific administration plans when determining total supply needs. [1]

BAC Water Reconstitution

Practitioner-reported approaches commonly involve reconstitution using bacteriostatic water. One example concentration uses 2 mL of bacteriostatic water per 10 mg vial, yielding a concentration of 5 mg/mL. Reconstitution practices vary according to institutional protocols, desired concentration, and research requirements, and clinical judgment should guide all preparation procedures.

Storage Considerations

Retatrutide research material is generally stored in a refrigerator at 2°C to 8°C and protected from light. Reconstituted material should be used within the stability window specified by the manufacturer or testing laboratory.

For professionals evaluating research-grade suppliers when buying online, reviewing storage documentation, stability data, and purity testing reports remains an important quality-control step before finalizing any sourcing decisions.

Retatrutide Side Effects & Safety Profile

The most commonly reported Retatrutide side effects in Phase 2 studies were gastrointestinal: [1][2]

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation

These effects were generally managed through gradual dose escalation and were consistent with the class profile observed across GLP-1-based therapies.

Risk for Pancreatitis and Hair Loss

The risk of pancreatitis should be considered in the broader context of the GLP-1 receptor agonist class. Although clinical trials have not identified unexpected pancreatitis signals with Retatrutide, clinicians should remain vigilant for persistent abdominal pain, particularly during dose escalation. Appropriate monitoring remains warranted until larger Phase 3 datasets become available. [1][2]

Meanwhile, current evidence does not support a direct pharmacologic cause of hair loss with Retatrutide. Temporary telogen effluvium may occur secondary to rapid weight loss, caloric restriction, or significant metabolic changes — similar observations have been reported with other obesity therapies and are typically reversible. [1]

Cardiovascular Monitoring

Glucagon receptor agonism may contribute to elevated resting heart rate in some individuals. While the clinical significance remains under investigation, practitioners should monitor cardiovascular parameters in patients with pre-existing risk factors. [1]

Long-Term Safety Data

The longest fully published, peer-reviewed controlled data currently extend to approximately 48 weeks from Phase 2 trials. Definitive long-term safety and efficacy profiles remain dependent on the completion of the ongoing Phase 3 TRIUMPH program and subsequent post-marketing surveillance. [3][4]

Is Retatrutide FDA Approved? Legal Status & Regulatory Context

Retatrutide has not received approval from the U.S. Food and Drug Administration for obesity, type 2 diabetes, or any other indication as of mid-2026. The compound is currently being studied in the Phase 3 TRIUMPH clinical trial program, with primary readouts actively emerging. Any NDA or BLA submission is anticipated only after Phase 3 completion and regulatory review. [3][4]

  • United States: Retatrutide remains an investigational compound and is not available for routine clinical prescribing outside authorized clinical trial settings. This distinguishes it clearly from approved therapies such as Tirzepatide and Semaglutide, which have established prescribing information and full regulatory oversight. [3][4]
  • European Union (EU) and Australia: Retatrutide has not been approved in the European Union or Australia. No major regulatory agency has authorized its commercial therapeutic use, and access remains limited to research settings and approved clinical studies.

Retatrutide Alternatives for Weight Loss

For practitioners evaluating Retatrutide alternatives for weight loss, the primary approved options are Tirzepatide, an FDA-approved dual GLP-1/GIP receptor agonist (Mounjaro/Zepbound), and Semaglutide, an FDA-approved GLP-1 receptor agonist (Ozempic/Wegovy). Both have established efficacy and safety data and approved prescribing pathways, whereas Retatrutide remains investigational pending Phase 3 outcomes. [1][2]

Retatrutide vs Tirzepatide & Semaglutide

Clinicians increasingly compare Retatrutide with established incretin-based treatments to evaluate mechanistic differences, Phase 2 efficacy data, and clinical positioning.

Methodological note: There are currently no prospective, randomized head-to-head clinical trials comparing Retatrutide directly with Tirzepatide or Semaglutide. These cross-trial comparisons are indirect and hypothesis-generating only, as baseline patient populations, trial durations, and specific endpoints differ across the STEP, SURMOUNT, and Retatrutide Phase 2 programs.

Retatrutide vs Tirzepatide

Tirzepatide is the closest approved comparator to Retatrutide because both activate GLP-1 and GIP receptors. Retatrutide adds glucagon receptor agonism, which may contribute to increased energy expenditure, enhanced hepatic lipolysis, and liver fat reduction — mechanisms absent from Tirzepatide’s profile. In Phase 2 data from Jastreboff et al. (NEJM, 2023), Retatrutide achieved approximately 24% mean weight reduction at 12 mg at 48 weeks; Tirzepatide demonstrated approximately 21% at 15 mg in the SURMOUNT-1 trial — but these figures come from separate trials with different populations and should not be interpreted as a direct comparison. [1]

Tirzepatide remains the FDA-approved standard of care. For research protocols in which glucagon-mediated energy expenditure and hepatic fat reduction are relevant endpoints, Retatrutide’s additional receptor arm represents the key mechanistic distinction to evaluate relative to the established dual-agonist baseline. [1][3]

Retatrutide vs Semaglutide

Semaglutide is a GLP-1 receptor agonist and one of the most widely prescribed weight-loss agents globally. Retatrutide combines agonism at GLP-1, GIP, and glucagon receptors, producing a substantially broader metabolic profile. Phase 2 data from Jastreboff et al. (NEJM, 2023) showed approximately 24% mean weight reduction with Retatrutide at 12 mg at 48 weeks, while Semaglutide demonstrated approximately 15% at 2.4 mg weekly in the STEP trials — again, these are cross-trial figures drawn from studies with different designs and populations, and should be treated as indirect. [1]

Semaglutide benefits from extensive clinical experience, long-term safety data, and full regulatory approval, whereas Retatrutide remains investigational, with only Phase 2 data. The Phase 3 TRIUMPH results will be central to determining whether the triple-agonist approach offers meaningful clinical advantages over established GLP-1 monotherapy across broader patient populations. [1][3]

Sourcing Research-Grade Retatrutide: Guidance for Licensed Professionals

Research-grade Retatrutide is available only to qualified licensed professionals. Practitioners considering where to buy Retatrutide wholesale for institutional or clinical research purposes should prioritize suppliers that can provide verifiable purity documentation, including a certificate of analysis (CoA), LOT number traceability, and independent third-party testing results.

Sourcing from unverified vendors carries real risk: inconsistent peptide concentrations, absent batch documentation, and inadequate cold-chain handling can all compromise research integrity. Before finalizing any procurement decision, researchers should check for wholesale supply documentation standards and confirm that supplier credentials align with institutional requirements.

Practitioners seeking guidance on where to buy Retatrutide online or through verified research-grade suppliers may contact the Direct Doctor Supply support team for sourcing direction and documentation support. The support team can connect licensed professionals with verified research-grade suppliers and provide guidance on the documentation standards commonly required for institutional procurement.

FAQs

1. What is Retatrutide?

Retatrutide is an investigational GLP-1, GIP, and glucagon receptor triple agonist developed by Eli Lilly. It is currently being studied for the management of obesity, insulin resistance, and metabolic disease through the Phase 3 TRIUMPH program. Phase 2 data published by Jastreboff et al. (NEJM, 2023) reported a mean body weight reduction of approximately 24% at 48 weeks. [1]

2. Is Retatrutide FDA-approved?

No. Retatrutide remains investigational and has not received FDA approval as of mid-2026. Primary Phase 3 TRIUMPH readouts are currently ongoing. Current FDA-approved alternatives include Tirzepatide and Semaglutide. [3][4]

3. Is Retatrutide safe?

Phase 2 clinical trials demonstrated a safety profile generally consistent with the GLP-1/GIP/glucagon agonist class, with no unexpected safety signals during the 48-week study period. Long-term safety data remain under investigation and await completion of Phase 3 and post-marketing surveillance. [1][3]

4. What are the Retatrutide side effects?

The most commonly reported adverse effects include nausea, vomiting, diarrhea, and constipation. These effects are generally dose-related and often improve with gradual dose escalation. Class-level risk for pancreatitis should also be considered, along with possible elevated resting heart rate related to glucagon receptor activity. [1]

5. How long will 10mg of Retatrutide last?

With once-weekly administration, a 10 mg vial generally serves as the baseline for a single high-dose treatment. Because clinical trial protocols specify titration steps such as 2 mg, 4 mg, 9 mg, or 12 mg, a 10 mg vial may yield multiple smaller starter doses depending on the phase of the protocol. [1]

6. How does Retatrutide compare to Tirzepatide?

Retatrutide combines agonism at the GLP-1, GIP, and glucagon receptors, while Tirzepatide targets only the GLP-1 and GIP receptors. Phase 2 data showed approximately 24% mean weight reduction with Retatrutide at 12 mg versus approximately 21% with Tirzepatide at 15 mg in SURMOUNT-1 — these are indirect, cross-trial figures. Tirzepatide is FDA-approved; Retatrutide is investigational. [1]

7. How does Retatrutide compare to Semaglutide?

Retatrutide employs triple agonism at the GLP-1, GIP, and glucagon receptors, whereas Semaglutide is a GLP-1-only receptor agonist. Phase 2 data suggest approximately a 24% weight reduction with Retatrutide versus approximately a 15% weight reduction with Semaglutide in STEP trials — indirect cross-trial comparison only. Semaglutide remains FDA-approved with an extensive real-world safety record; Retatrutide is investigational. [1]

Citations

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:1056/NEJMoa2301972
  2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi:1016/S0140-6736(23)01053-X
  3. Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93. doi:10.1111/dom.70209
  4. gov. A Study of Retatrutide (LY3437943) Once Weekly in Participants With Obesity or Overweight and Weight-Related Comorbidities. NCT05931367. https://clinicaltrials.gov/study/NCT05931367
  5. Eli Lilly and Company. Lilly’s phase 2 retatrutide results published in The New England Journal of Medicine. https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Content prepared by Direct Doctor Supply’s editorial team.

Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.

SVG Logo Color cropped

info@directdoctorsupply.com

+1-800-325-7104

Book a MeetingTrack delivery
Trustpilot

Supported payment providers

Visa Mastercard American Express Google Pay Apple Pay

*Apple Pay and Google Pay are available via a personalized link provided by your account manager.

🔒 Transactions on this website meet strict PCI DSS compliance for your safety.

Product authenticity guaranteed: all products are sourced from licensed distributors and traceable by LOT number.

Company
  • About Us
  • FAQ
  • Contact Us
  • Referral Program
  • Sitemap
Follow Us
  • Facebook
  • Instagram
  • LinkedIn
Company
  • About Us
  • FAQ
  • Contact Us
  • Referral Program
Follow Us
  • Facebook
  • Instagram
  • Linkedin
Products
  • Anaesthetics
  • Body Sculpting
  • Botulinum Toxin
  • Needles and Cannula
  • Filler Removal
  • Dermal Fillers
  • Eyelash Enhancers
  • Fat Removal
  • Gynecology
  • Mesotherapy
  • Orthopaedic Injections
  • Peels and Masks
  • PRP Kits
  • Skincare
  • Threads
  • Weight Management
Products
  • Anaesthetics
  • Body Sculpting
  • Botulinum Toxin
  • Needles and Cannula
  • Filler Removal
  • Dermal Fillers
  • Eyelash Enhancers
  • Fat Removal
  • Gynecology
  • Mesotherapy
  • Orthopaedic Injections
  • Peels and Masks
  • PRP Kits
  • Skincare
  • Threads
  • Weight Management

All peptide products sold by Direct Doctor Supply are Research Use Only (RUO) and intended solely for laboratory and scientific research. They are not FDA-approved and not for human or veterinary use, clinical, diagnostic, or therapeutic purposes. By purchasing RUO materials, you confirm they will be handled by qualified personnel in a proper research setting and in compliance with regulations. Products must not be administered to humans or animals or represented as safe or effective for medical use. Use is at your own risk; Direct Doctor Supply assumes no liability for misuse or regulatory issues.

2026 Direct Doctor Supply All rights reserved.
Terms Of Use Privacy Policy Refund and Replacement Shipping & Delivery